SK83895A3 - Oligonucleotides for inhibition of expression of izoprenyl-proteineous transferases - Google Patents

Oligonucleotides for inhibition of expression of izoprenyl-proteineous transferases Download PDF

Info

Publication number
SK83895A3
SK83895A3 SK838-95A SK83895A SK83895A3 SK 83895 A3 SK83895 A3 SK 83895A3 SK 83895 A SK83895 A SK 83895A SK 83895 A3 SK83895 A3 SK 83895A3
Authority
SK
Slovakia
Prior art keywords
seq
oligonucleotide
antisense
oligonucleotides
nucleotide
Prior art date
Application number
SK838-95A
Other languages
English (en)
Slovak (sk)
Inventor
Soudhir Colote
Eduardo Pirotzky
Original Assignee
Scras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scras filed Critical Scras
Publication of SK83895A3 publication Critical patent/SK83895A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01029—Geranylgeranyl diphosphate synthase (2.5.1.29)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
SK838-95A 1994-06-29 1995-06-26 Oligonucleotides for inhibition of expression of izoprenyl-proteineous transferases SK83895A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9413035A GB9413035D0 (en) 1994-06-29 1994-06-29 Antisense oligonucleeotides

Publications (1)

Publication Number Publication Date
SK83895A3 true SK83895A3 (en) 1996-05-08

Family

ID=10757497

Family Applications (1)

Application Number Title Priority Date Filing Date
SK838-95A SK83895A3 (en) 1994-06-29 1995-06-26 Oligonucleotides for inhibition of expression of izoprenyl-proteineous transferases

Country Status (25)

Country Link
US (1) US5856461A (pt)
EP (1) EP0692535A1 (pt)
JP (1) JPH0851985A (pt)
KR (1) KR960000914A (pt)
CN (1) CN1124142A (pt)
AU (1) AU689887B2 (pt)
BR (1) BR9503015A (pt)
CA (1) CA2152233A1 (pt)
CZ (1) CZ291496B6 (pt)
DZ (1) DZ1903A1 (pt)
FI (1) FI953170A (pt)
FR (2) FR2721930B1 (pt)
GB (2) GB9413035D0 (pt)
HU (1) HU219823B (pt)
IE (1) IE950477A1 (pt)
MA (1) MA23595A1 (pt)
NO (1) NO952601L (pt)
NZ (1) NZ272398A (pt)
OA (1) OA10221A (pt)
PL (1) PL309384A1 (pt)
RU (1) RU2112766C1 (pt)
SE (1) SE9502259L (pt)
SK (1) SK83895A3 (pt)
TN (1) TNSN95068A1 (pt)
ZA (1) ZA955288B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226623A1 (en) * 1995-07-13 1997-01-30 University Of Cincinnati Compounds useful in the treatment of neurofibromatosis
CN1301731A (zh) * 1999-12-24 2001-07-04 上海博德基因开发有限公司 一种新的多肽——多异戊二烯基合成酶蛋白9和编码这种多肽的多核苷酸
WO2002046414A2 (en) * 2000-12-07 2002-06-13 Bristol-Myers Squibb Company Human g-protein coupled receptor expressed highly in kidney
US20030212017A1 (en) * 2002-05-10 2003-11-13 Isis Pharmaceuticals Inc. Antisense modulation of farnesyl transferase beta subunit expression
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
SI1667522T1 (en) 2003-09-09 2018-04-30 Geron Corporation Modified oligonucleotides for the inhibition of telomerase
US8785409B2 (en) * 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4571421A (en) * 1979-11-05 1986-02-18 Genentech, Inc. Mammalian gene for microbial expression
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5420245A (en) * 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5185248A (en) * 1990-05-08 1993-02-09 E. R. Squibb & Sons, Inc. Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation
KR100242671B1 (ko) * 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
NZ244820A (en) * 1991-10-25 1994-01-26 Isis Pharmaceuticals Inc Oligonucleotide inhibitor of epstein-barr virus.
US5348853A (en) * 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA

Also Published As

Publication number Publication date
NO952601D0 (no) 1995-06-28
PL309384A1 (en) 1996-01-08
ZA955288B (en) 1996-01-31
OA10221A (fr) 1997-09-19
MA23595A1 (fr) 1995-12-31
GB2290791A (en) 1996-01-10
BR9503015A (pt) 1996-06-04
NZ272398A (en) 1996-04-26
HU219823B (hu) 2001-08-28
GB2290791B (en) 1998-08-05
FI953170A (fi) 1995-12-30
FR2721930A1 (fr) 1996-01-05
US5856461A (en) 1999-01-05
CZ168895A3 (en) 1996-05-15
GB9413035D0 (en) 1994-08-17
DZ1903A1 (fr) 2002-02-17
SE9502259L (sv) 1995-12-30
AU689887B2 (en) 1998-04-09
FR2721827A1 (fr) 1996-01-05
IE950477A1 (en) 1996-01-10
HUT72133A (en) 1996-03-28
EP0692535A1 (fr) 1996-01-17
CZ291496B6 (cs) 2003-03-12
SE9502259D0 (sv) 1995-06-21
RU95110774A (ru) 1997-04-20
KR960000914A (ko) 1996-01-25
GB9513246D0 (en) 1995-09-06
AU2329995A (en) 1996-01-11
TNSN95068A1 (fr) 1996-02-06
CA2152233A1 (en) 1995-12-30
RU2112766C1 (ru) 1998-06-10
NO952601L (no) 1996-01-02
JPH0851985A (ja) 1996-02-27
CN1124142A (zh) 1996-06-12
FI953170A0 (fi) 1995-06-27
HU9501913D0 (en) 1995-08-28
FR2721930B1 (fr) 1997-01-03

Similar Documents

Publication Publication Date Title
EP3356529B1 (en) Compositions and methods for inhibiting gene expression of lpa
JP3231779B2 (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
JP2023156455A (ja) 第ｘｉｉ因子の遺伝子発現を阻害するための組成物と方法
CA2140649C (en) Hybrid oligonucleotide phosphorothioates
JP4643906B2 (ja) 遺伝子発現の標的化阻害のための合成二本鎖オリゴヌクレオチド
JP3054745B2 (ja) ｒａｆ遺伝子発現のアンチセンスオリゴヌクレオチド調節
US5892023A (en) Anti sense oligonucleotides for blocking IgE receptor synthesis
EP0736093B1 (en) ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL
CA2152672A1 (en) Oligomers having improved stability at acid ph
SK83895A3 (en) Oligonucleotides for inhibition of expression of izoprenyl-proteineous transferases
ES2280098T3 (es) Oligonucleotidos antisentido contra timidilato sintasa.
EPA et al. Enhanced downregulation of the p75 nerve growth factor receptor by cholesteryl and bis-cholesteryl antisense oligonucleotides
EP1071764B1 (en) Antisense oligonucleotides for the inhibition of integrin alphav-subunit expression
EP0906123A1 (en) OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA
Dagle et al. Selective degradation of targeted mRNAs using partially modified oligonucleotides
US20030176384A1 (en) Antisense oligonucleotides for the inhibition of integrin alphav -subunit expression
Galderisi et al. Clinical trials of a new class of therapeutic agents: antisense oligonucleotides
Wu Cellular uptake of a c-myc antisense oligonucleotide into Rauscher Red 5-1.5 cells